comparemela.com

Latest Breaking News On - ஃப்ட் ஏப்ரல் - Page 2 : comparemela.com

How effective is the Pfizer-BioNTech (BNT162b2) COVID-19 vaccine? A real-world study in Sweden

Investigating a population in southern Sweden, a new study has found that a single dose of the vaccine is only about 42% effective in preventing coronavirus disease 2019 (COVID-19). But seven days after the second dose, the vaccine can prevent COVID-19 in 86% of the population.

Interfering RNA nanoparticles could be a potential COVID-19 therapy

Interfering RNA nanoparticles could be a potential COVID-19 therapy Study shows lipid nanoparticle-based siRNA is potent in suppressing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the causative agent of coronavirus disease 2019 (COVID-19) – in cells as well as in mice models. COVID-19 cases continue to increase all over the world. Several vaccines have now been approved and are being administered. However, with new variants of the virus emerging, there have been questions around how effective the vaccines will be. The genome in coronaviruses is encoded by ribonucleic acid (RNA), making them vulnerable to RNA interference, especially when they are delivered to the lungs. However, there are few therapies that target viral RNA.

Screening drug candidates for COVID-19 treatment using computational methods

Screening drug candidates for COVID-19 treatment using computational methods
news-medical.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news-medical.net Daily Mail and Mail on Sunday newspapers.

Modeling study suggests how different SARS-CoV-2 mutations prevent antibody binding

Modeling study suggests how different SARS-CoV-2 mutations prevent antibody binding Using three classes of antibodies, researchers modeled their binding to the SARS-CoV-2 virus spike protein. They found binding to key residues in current mutations changes how the spike protein moves and can lead to binding resistance. The spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) adopts several conformations when it binds to host receptors. Antibodies against the virus often compete with the host receptors to bind to the spike protein and interfere with the processes that change the spike protein conformation. Some antibodies can bind to different parts of the spike protein simultaneously, providing a more potent neutralizing capacity. Class I antibodies have a considerable overlap with the angiotensin-converting enzyme 2 (ACE2) receptor and bind when the receptor-binding domain (RBD) is in the open or up conformation.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.